Company attributes
Other attributes
G1 Therapeutics is a publicly traded, clinical-stage biopharmaceutical company based in Research Triangle Park, North Carolina that was founded in 2008 by Kwok-Kin Wong and Norman Sharpless. It focuses on the discovery, development, and delivery of therapies that improve the lives of cancer patients.
The company is currently running three clinical-stage programs, trilaciclib, lerociclib, and G1T48. They are designed to enable more effective combination treatment strategies and improve patient outcomes across multiple oncology indications. Trilaciclib and lerociclib are CDK4/6 indicators, which have broad therapeutical potential in many forms of cancer. G1T48 on the other hand is a oral selective estrogen receptor degrader (SERD), which is targeted for the treatment of ER+ breast cancer.
Trilaciclib is a first-in-class myelopreservation therapy that is designed to improve outcomes of patients who receive chemotherapy by preserving hematopoietic stem and progenitor cell (HSPC) and immune system functions. It is a short-acting intravenous CDK4/6 administered prior to chemotherapy. Trilaciclib is being evaluated in four randomized Phase 2 trials. In December 2018, G1 announced positive topline results from these trials.
Lerociclib is a potential oral CDK4/6 inhibitor that is being developed for use in combination with other targeted therapies in multiple oncology indications. The product is being evaluated in two Phase 1/2 clinical trials, a trial in combination with Faslodex for patients with estrogen receptor positive, HER2-negative (ER+, HER2-) breast cancer and a trial in combination with Tagrisso in EGFRm non-small cell lung cancer. The latter trial is a clinical trial collaboration with AstraZeneca.
G1T48 is an oral selective estrogen receptor degreader (SERD). G1 has initiated a Phase 1/2a clinical trial of G1T48 in estrogen-receptor positive, HER2-negative (ER+, HER2-) breast cancer. The company is also planning to combine lerociclib and G1T48 as a potential all-oral regiment in this indication.
In 2017, G1 also entered into a clinical trial collaboration with AstraZeneca to evaluate the latter company's epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).
On October 12, 2012 G1 Therapeutics completed a venture funding round with $762,900 in funding from undisclosed investors.
On October 16, 2013 G1 Therapeutics completed their series A funding round with $12.5 million in funding from MedImmune Ventures (lead investor), Mountain Group Capital, and Hatteras Venture Partners.
On February 5, 2015 G1 Therapeutics completed their series B funding round with $33 million in funding from Ra Capital Management (lead investor), Eshelman Ventures (lead investor), Mountain Group Capital, MedImmune Ventures, Lumira Ventures, and Hatteras Venture Partners.
On May 11, 2016 G1 Therapeutics completed their series C funding round with $47 million in funding from Cormorant Asset Management (lead investor), Tavistock Life Sciences, Rock Springs Capital, RA Capital Management, Mountain Group Capital, MedImmune Ventures, Lumira Ventures, Hatteras Venture Partners, Franklin Templeton Investments, Eshelman Ventures, and Cowen Group.
